Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 95% Improvement Relative Risk Case 42% c19early.org/d Karonova et al. Vitamin D for COVID-19 RCT Prophylaxis Favors high dose Favors low dose
Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers
Karonova et al., Nutrients, doi:10.3390/nu14030505
Karonova et al., Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers, Nutrients, doi:10.3390/nu14030505
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT in Russia with 45 high dose vitamin D patients (50,000IU/wk for 2 wks followed by 5,000IU/day) and 46 low dose patients (2,000IU/day), showing lower cases and lower symptomatic cases with high dose treatment.
risk of symptomatic case, 94.6% lower, RR 0.05, p = 0.002, treatment 0 of 38 (0.0%), control 9 of 40 (22.5%), NNT 4.4, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of case, 41.5% lower, RR 0.58, p = 0.10, treatment 10 of 38 (26.3%), control 18 of 40 (45.0%), NNT 5.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karonova et al., 24 Jan 2022, Randomized Controlled Trial, Russia, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers Tatiana L. Karonova 1, * , Alena T. Chernikova 1 , Ksenia A. Golovatyuk 1 , Ekaterina S. Bykova 1 , William B. Grant 2 , Olga V. Kalinina 1 , Elena N. Grineva 1 and Evgeny V. Shlyakhto 1 1 2 *   Citation: Karonova, T.L.; Chernikova, A.T.; Golovatyuk, K.A.; Bykova, E.S.; Grant, W.B.; Kalinina, O.V.; Grineva, E.N.; Shlyakhto, E.V. Vitamin D Intake May Reduce SARS-CoV-2 Infection Morbidity in Health Care Workers. Nutrients 2022, 14, 505. https://doi.org/10.3390/ nu14030505 Academic Editor: Roberto Iacone Received: 29 December 2021 Accepted: 21 January 2022 Clinical Endocrinology Laboratory, Department of Endocrinology, Almazov National Medical Research Centre, 194021 Saint Petersburg, Russia; arabicaa@gmail.com (A.T.C.); ksgolovatiuk@gmail.com (K.A.G.); bykova160718@gmail.com (E.S.B.); olgakalinina@mail.ru (O.V.K.); grineva_e@mail.ru (E.N.G.); shlyakhto_ev@almazovcentre.ru (E.V.S.) Sunlight, Nutrition, and Health Research Center, San Francisco, CA 94164-1603, USA; williamgrant08@comcast.net Correspondence: karonova@mai.ru; Tel.: +7-921-310-60-41 Abstract: In the last 2 years, observational studies have shown that a low 25-hydroxyvitamin D (25(OH)D) level affected the severity of infection with the novel coronavirus (COVID-19). This study aimed to analyze the potential effect of vitamin D supplementation in reducing SARS-CoV-2 infection morbidity and severity in health care workers. Of 128 health care workers, 91 (consisting of 38 medical doctors (42%), 38 nurses (42%), and 15 medical attendants (16%)) were randomized into two groups receiving vitamin D supplementation. Participants of group I (n = 45) received water-soluble cholecalciferol at a dose of 50,000 IU/week for 2 consecutive weeks, followed by 5000 IU/day for the rest of the study. Participants of group II (n = 46) received water-soluble cholecalciferol at a dose of 2000 IU/day. For both groups, treatment lasted 3 months. Baseline serum 25(OH)D level in health care workers varied from 3.0 to 65.1 ng/mL (median, 17.7 (interquartile range, 12.2; 24.7) ng/mL). Vitamin D deficiency, insufficiency, and normal vitamin D status were diagnosed in 60%, 30%, and 10%, respectively. Only 78 subjects completed the study. Vitamin D supplementation was associated with an increase in serum 25(OH)D level, but only intake of 5000 IU/day was accompanied by normalization of serum 25(OH)D level, which occurred in 53% of cases. Neither vitamin D intake nor vitamin D deficiency/insufficiency were associated with a decrease in SARS-CoV-2 morbidity (odds ratio = 2.27; 95% confidence interval, 0.72 to 7.12). However, subjects receiving high-dose vitamin D had only asymptomatic SARS-CoV-2 in 10 (26%) cases; at the same time, participants who received 2000 IU/day showed twice as many SARS-CoV-2 cases, with mild clinical features in half of them. Keywords: COVID-19; SARS-CoV-2; vitamin D; 25(OH)D; health care workers Published: 24 January 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit